The beneficial effects of combined therapy of propranolol d isomer and captopril in ischemic acute renal failure in rats

Ishigami, M.; Maeda, T.; Shimada, Y.; Yabuki, S.; Stowe, N.T.

Journal of the Medical Society of Toho University 35(1): 62-70


ISSN/ISBN: 0040-8670
Accession: 006606060

Download citation:  

Article/Abstract emailed within 1 workday
Payments are secure & encrypted
Powered by Stripe
Powered by PayPal

The effectiveness of combination therapy with d-isomer of propranolol (d-propranolol) and captopril in preventing the reduction of glomerular filtration (GFR) following 45 min. renal ischemia was studied in rats. Kidney function affected by ischemia was significantly more improved by combination therapy with d-propranolol and captopril than by d-propranolol treatment alone. Captopril treatment alone did not show any significantly beneficial effect. In the untreated control group, GFR measured 2 hours after ischemia returned to only 13% of its pre-ischemia value, whereas with d-propranolol treatment and combination therapy with d-propranolol captopril it returned to 29% and 23% of its pre-ischemia value, respectively (p < 0.05). When GFR was measured 24 hours after ischemia, the combined treatment with d-propranolol and captopril was seen to have resulted in a significantly higher GFR value (305 .+-. 35 .mu.l/min/100g BW) compared to that of the d-propranolol group (173 .+-. 22 .mu.l/min/100g BW) or of the captopril group (102 .+-. 16 .mu.l/min/100g BW); the recovery of GFR was approximately six times greater in the combined therapy group than in the untreated group (54 .+-. 11 .mu.l/min/100g BW). Captopril treatment produced an increase of about 30% in renal blood flow (RBF) before the induction of renal ischemia and maintained RBF at significantly higher levels than in the untreated control group over the 2-hour recovery period following ischemia (3.2 .+-. 0.2 ml/min/100g BW VS 2.4 .+-. 0.2 ml/min/100g BW, p < 0.05). The mechanisms of the beneficial effect observed with this combined treatment are not clear at this time, but this therapeutic approach could be useful for exploring the pathophysiology of acute renal failure in addition to providing a pharmacological means of lessening the severity of post-ischemic acute renal failure.